Welcome to our dedicated page for Hydreight Tech news (Ticker: HYDTF), a resource for investors and traders seeking the latest updates and insights on Hydreight Tech stock.
Hydreight Technologies Inc. (HYDTF) regularly publishes news and corporate updates that reflect its role as a digital health and mobile clinic platform operating across all 50 U.S. states. Company announcements focus on platform expansion, treatment category launches, pharmacy and telehealth integrations, and operational milestones tied to its mobile clinical network and VSDHOne direct-to-consumer infrastructure.
Investors and observers following Hydreight’s news can expect coverage of financial and operational performance, such as revenue trends, product order volumes, and profitability metrics, as disclosed in quarterly updates. The company also reports on nurse network growth, license counts, and pharmacy order activity, which it uses as indicators of platform adoption and utilization across its ecosystem.
Hydreight’s news flow highlights developments in its multi-vertical healthcare model. Releases have described growth across categories including GLP-1 weight management, testosterone replacement therapy, peptides, NAD+ therapies, hair loss and skincare offerings, sexual health products, genetics and personalized genetic testing, and other wellness and longevity services. Additional updates cover expansions into at-home and preventive testing, such as the company’s entry into the at-home STI pre-screening market through an exclusive distribution agreement for rapid testing kits.
Corporate communications also address strategic initiatives, including enhancements to the VSDHOne platform, investments in modular architecture, pharmacy partnerships such as the stake in Perfect Scripts, and financing activities like convertible debenture offerings. Recognition in programs such as the Deloitte Technology Fast 500™ and the TSX Venture Exchange Top 50 is another recurring theme in Hydreight’s news.
For readers tracking HYDTF, the news page offers a centralized view of how Hydreight’s digital health infrastructure, mobile clinic network, and direct-to-consumer platforms are evolving over time. Regular updates provide context on the company’s operational metrics, treatment verticals, and strategic priorities within the U.S. digital health and wellness market.
Hydreight Technologies (OTC: HYDTF) reported exceptional growth in its VSDHOne platform, with July orders reaching 35,642 SKUs - more than triple the projected 10,000 orders. The company is now targeting 55,000 SKU orders for August as it progresses toward its 2025 goal of 1.3 million total orders.
The company announced a strategic partnership with Perfect Scripts, gaining access to 503B outsourcing facilities for large-batch drug compounding. This integration enables nationwide API connectivity, automated prescription processing, and enhanced fulfillment capabilities. Additionally, Hydreight launched its Marketing Solutions subsidiary to provide turnkey marketing services to licensees and telehealth partners.
The company also announced the resignation of director Gabi Kabazo, effective August 8, 2025.
Hydreight Technologies (OTCQB: HYDTF), a telehealth and mobile medical services company, has been invited to participate in the Canaccord Genuity 45th Annual Growth Conference on August 12-13, 2025, in Boston. CEO Shane Madden and Board Chair Shafin Diamond Tejani will represent the company, discussing its growth strategy and new offerings.
The company will also host an investor webinar on July 24, 2025, focusing on the Perfect Scripts Acquisition. Notably, Hydreight reported 34% year-over-year revenue growth in Q1 and was recently ranked as the #56 fastest-growing company in North America on the 2024 Deloitte Technology Fast 500™.
Hydreight Technologies (OTCQB: HYDTF) has appointed Dr. Jeremy Roebuck as a director of the company, effective May 5, 2025. Dr. Roebuck, who has served on Hydreight's Board of Advisors since December 12, 2022, fills the vacancy created by the resignation of Alexandros Tzilios. Hydreight is a North American integrated mobile clinical network of nurses, doctors, and pharmacy distribution.
Dr. Roebuck expressed enthusiasm about joining the board at a crucial growth phase, highlighting the company's focus on delivering healthcare through a compliant, tech-enabled platform. He aims to contribute to scaling the platform and expanding Hydreight's presence across North America.
Hydreight Technologies reported strong financial results for Q4 and full-year 2024, marking significant growth milestones. The company achieved record revenue of $22.32 million in topline revenue (up 31% from 2023) and $16.04 million in GAAP revenue (up 39% from 2023).
Key achievements include reaching positive Adjusted EBITDA of $490K compared to -$1.38M in 2023, and positive cash flow from operations. The company's success was recognized through rankings on Deloitte's Technology Fast 50™ (#9 in Canada) and Fast 500™ (#56 in North America).
The mobile healthcare platform, operating across all 50 U.S. states, secured $5.4M in financing and expanded its services through VSDHOne platform. With a network of 3,000+ nurses and 200+ physicians serving 700+ cities, Hydreight's 2025 strategy focuses on scaling franchise partnerships, improving pharmacy margins, and launching new wellness categories.
Hydreight Technologies (TSXV: NURS) (OTCQB: HYDTF) announced its upcoming presentation at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025. CEO Shane Madden will present at 12:30 PM PST and host a Q&A session.
The company is building one of the largest mobile clinical networks in the US, offering services like weight loss treatments, hormone therapy, IV wellness, and at-home testing. Recent achievements include:
- Launch of Liraglutide and sublingual semaglutide on VSDHOne platform
- US partnership with 'Dr. Frank's Method' GLP-1 weight-loss brand serving 70,000+ clients
- Launch of $10M health accelerator fund for emerging healthcare brands
- Ranked #13 on Financial Times' Americas' Fastest Growing Companies 2025
- #56 on Deloitte's Technology Fast 500™
- Top 50 on TSX Venture 50
Hydreight Technologies (HYDTF) has expanded its VSDHOne platform by launching Liraglutide, enhancing its GLP-1 weight management portfolio. The company's comprehensive GLP-1 offerings now include Semaglutide (weekly injectable), Tirzepatide (dual-action, weekly injectable), Liraglutide (daily injectable), and Sublingual & Buccal GLP-1s (needle-free administration).
The addition of Liraglutide introduces a stable, patent-free option amid increasing GLP-1 medication demand. The VSDHOne platform facilitates telehealth consultation, prescription, and nationwide delivery across 50 US states. With over 400 licenses sold across the U.S., Hydreight's platform supports multiple delivery methods including injectables, sublingual, and buccal options.
Notable achievements include ranking 56th on the 2024 Deloitte Technology Fast 500™, recognition as a Top 50 TSX Venture Exchange Company, and ranking 13th among Americas' Fastest Growing Companies by Financial Times in 2025.
Hydreight Technologies (HYDTF) has announced a strategic partnership with renowned endocrinologist Dr. Franklin Joseph to launch his successful weight-loss brand, 'Dr. Frank's Method,' in the United States through their VSDHOne telehealth platform.
The partnership combines Dr. Frank's GLP-1 weight-loss methodology, which has served over 500,000 global patients, with Hydreight's nationwide telehealth infrastructure. The program includes access to branded GLP-1 medications, specialist weight-loss nurses, and personalized lifestyle support.
Key partnership terms include:
- 50/50 profit-sharing structure
- Waived platform fees from Hydreight
- Committed monthly U.S. marketing spend from Dr. Frank
This collaboration targets the expanding U.S. weight-loss market, where over 42.4% of adults have obesity. The global weight-loss market is projected to exceed $400 billion by 2030, with GLP-1 prescriptions showing a 400% increase and spending rising by 500%.
FAQ
What is the current stock price of Hydreight Tech (HYDTF)?
What is the market cap of Hydreight Tech (HYDTF)?
